Tamoxifen citrate salt

CHF 75.00
In stock
CDX-T0201-G0011 gCHF 75.00
CDX-T0201-G0055 gCHF 299.00
More Information
Product Details
Synonyms (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; ICI 46474; Istubal; Kessar; Noltam; Nolvadex; TMX; Valodex; Zemide
Product Type Chemical
Formula C26H29NO . C6H8O7
MW 563.64
CAS 54965-24-1
Purity Chemicals ≥98%
Appearance White powder.
Solubility Soluble in DMSO or methanol. Slightly soluble in ethanol.
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Smiles CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/CC)C=C1)C.OC(CC(O)(C(O)=O)CC(O)=O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Selective estrogen receptor modulator (SERM) used as adjuvant therapy for estrogen-dependent breast cancer. Antagonist of ER action in breast tissue and breast cancer cells and ER agonist in bone, uterus, and the cardiovasculature system. This prodrug is metabolized by cytochrome P450 (CYP450) enzymes to the active metabolites N-desmethyl-TMX, 4-hydroxy-N-desmethyl-TMX (endoxifen) and 4-hydroxy-TMX (afimoxifene). N,N-Didesmethyl-4-hydroxytamoxifen (norendoxifen), another active metabolite has been found to act as a potent competitive aromatase inhibitor and may also be involved in its antiestrogenic activity. Binds microsomal antiestrogen binding sites, altering cholesterol esterification at therapeutic doses and impacting breast cancer cell differentiation, apoptosis, and autophagy. Protein kinase C (PKC) inhibitor and anti-angiogenetic factor.

Product References

(1) K. B. Horwitz & W. L. McGuire; J. Biol. Chem. 253, 8185 (1978) | (2) V.C. Jordan, et al.; Cancer Treat. Rep. 64, 745 (1980) | (3) C.A. O'Brian, et al.; Cancer Res. 45, 2462 (1985) | (4) K.J. Edwards, et al.; J. Med. Chem. 35, 2753 (1992) | (5) M. Clarke, et al.; Lancet 351, 1451 (1998) | (6) D.A. Tonetti & V.C. Jordan; Mol. Med. Today 2, 218 (1996) | (7) J.M. Hall, et al.; J. Biol. Chem. 276, 36869 (2001) | (8) P. Thomas, et al.; Endocrinol. 146, 624 (2005) | (9) M.S. Singh, et al.; Breast 20, 111 (2011) | (10) P. de Medina, et al.; Chem. Phys. Lip. 164, 432 (2011) | (11) V.K. Todorova, et al.; Cancer Chemother. Pharmacol. 67, 285 (2011)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.